全文获取类型
收费全文 | 467篇 |
免费 | 33篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 10篇 |
妇产科学 | 7篇 |
基础医学 | 89篇 |
口腔科学 | 3篇 |
临床医学 | 60篇 |
内科学 | 102篇 |
皮肤病学 | 21篇 |
神经病学 | 66篇 |
特种医学 | 5篇 |
外科学 | 24篇 |
综合类 | 1篇 |
预防医学 | 52篇 |
眼科学 | 4篇 |
药学 | 26篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2024年 | 2篇 |
2023年 | 27篇 |
2022年 | 11篇 |
2021年 | 24篇 |
2020年 | 20篇 |
2019年 | 20篇 |
2018年 | 23篇 |
2017年 | 12篇 |
2016年 | 21篇 |
2015年 | 13篇 |
2014年 | 24篇 |
2013年 | 22篇 |
2012年 | 50篇 |
2011年 | 31篇 |
2010年 | 13篇 |
2009年 | 15篇 |
2008年 | 24篇 |
2007年 | 29篇 |
2006年 | 24篇 |
2005年 | 18篇 |
2004年 | 15篇 |
2003年 | 12篇 |
2002年 | 17篇 |
2001年 | 5篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1995年 | 4篇 |
1993年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1976年 | 1篇 |
1958年 | 1篇 |
1943年 | 1篇 |
1933年 | 1篇 |
1931年 | 1篇 |
排序方式: 共有503条查询结果,搜索用时 15 毫秒
1.
2.
Pharmacokinetics of nebulized and oral procaterol in asthmatic and non‐asthmatic subjects in relation to doping analysis 下载免费PDF全文
Nanna Krogh Vibeke Backer Sebastian Rzeppa Peter Hemmersbach Morten Hostrup 《Drug testing and analysis》2016,8(10):1056-1064
The purpose of the present study was to investigate pharmacokinetics of procaterol in asthmatics and non‐asthmatics after nebulized and oral administration in relation to doping. Ten asthmatic and ten non‐asthmatic subjects underwent two pharmacokinetic trials. At first trial, 4 µg procaterol was administered as nebulization. At second trial, 100 µg procaterol was administered orally. Serum and urine samples were collected before and after administration of procaterol. Samples were analyzed by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Serum and urine concentrations of procaterol were markedly higher after oral administration compared to nebulized administration. After oral administration, serum procaterol concentration‐time area under the curve (AUC) was higher (P ≤ 0.05) for asthmatics than non‐asthmatics. Likewise, urine concentrations were higher (P ≤ 0.01) for asthmatics than non‐asthmatics 4 (47 ± 12 vs. 28 ± 9 ng/mL) and 8 h (39 ± 9 vs. 15 ± 5 ng/mL) after oral administration. Detection of serum procaterol was difficult after nebulized administration with 38 samples (27%) below limit of quantification (LOQ) and only trends were observed. No differences were observed between asthmatics and non‐asthmatics in the urine concentrations of procaterol after nebulized administration. In summary, our data showed that asthmatics had higher urine concentrations of procaterol than non‐asthmatics after oral administration of 100 µg, whereas no difference was observed between the groups after nebulized administration. For doping control purposes, our observations indicate that it is possible to differentiate therapeutic nebulized administration of procaterol from prohibited use of oral procaterol. Copyright © 2016 John Wiley & Sons, Ltd. 相似文献
3.
Mustapha Itani Sandra Sif Gylfadottir Thomas Krigrd Alexander Gramm Kristensen Diana Hedevang Christensen Pall Karlsson Sren Mller Henning Andersen Hatice Tankisi Jens Steen Nielsen Troels Staehelin Jensen Reimar Wernich Thomsen Nanna Brix Finnerup Sren Hein Sindrup 《Journal of the peripheral nervous system : JPNS》2021,26(1):55-65
Diabetic polyneuropathy (DPN) can be classified based on fiber diameter into three subtypes: small fiber neuropathy (SFN), large fiber neuropathy (LFN), and mixed fiber neuropathy (MFN). We examined the effect of different diagnostic models on the frequency of polyneuropathy subtypes in type 2 diabetes patients with DPN. This study was based on patients from the Danish Center for Strategic Research in Type 2 Diabetes cohort. We defined DPN as probable or definite DPN according to the Toronto Consensus Criteria. DPN was then subtyped according to four distinct diagnostic models. A total of 277 diabetes patients (214 with DPN and 63 with no DPN) were included in the study. We found a considerable variation in polyneuropathy subtypes by applying different diagnostic models independent of the degree of certainty of DPN diagnosis. For probable and definite DPN, the frequency of subtypes across diagnostic models varied from: 1.4% to 13.1% for SFN, 9.3% to 21.5% for LFN, 51.4% to 83.2% for MFN, and 0.5% to 14.5% for non‐classifiable neuropathy (NCN). For the definite DPN group, the frequency of subtypes varied from: 1.6% to 13.5% for SFN, 5.6% to 20.6% for LFN, 61.9% to 89.7% for MFN, and 0.0% to 6.3% for NCN. The frequency of polyneuropathy subtypes depends on the type and number of criteria applied in a diagnostic model. Future consensus criteria should clearly define sensory functions to be tested, methods of testing, and how findings should be interpreted for both clinical practice and research purpose. 相似文献
4.
5.
Line Lykke Andersen Nanna M?rk Line S. Reinert Emil Kofod-Olsen Ryo Narita Sofie E. J?rgensen Kristian A. Skipper Klara H?ning Hans Henrik Gad Lars ?stergaard Torben F. ?rntoft Veit Hornung S?ren R. Paludan Jacob Giehm Mikkelsen Takashi Fujita Mette Christiansen Rune Hartmann Trine H. Mogensen 《The Journal of experimental medicine》2015,212(9):1371-1379
6.
Kristine Færch Dorte Vistisen Nanna Borup Johansen Marit Eika Jørgensen 《Current diabetes reports》2014,14(6):1-8
Prediabetes, covering individuals with impaired fasting glycemia, impaired glucose tolerance, or high-risk HbA1c levels, is associated with a ~20 % increased risk of developing cardiovascular disease (CVD) compared with normoglycemic individuals. It is well-known that lifestyle or pharmacologic interventions can prevent diabetes in prediabetic people; however, the evidence is less clear regarding prevention of CVD. Most diabetes prevention trials have failed to show beneficial effects on CVD morbidity and mortality despite significant improvements of CVD risk factors in individuals with prediabetes. Another challenge is how to estimate CVD risk in prediabetic people. In general, prediction models for CVD do not take glucose levels or prediabetes status into account, thereby underestimating CVD risk in these high-risk individuals. More evidence within risk stratification and management of CVD risk in prediabetes is needed in order to recommend useful and effective strategies for early prevention of CVD. 相似文献
7.
Mari Nanna ?ines Peter-Martin Krarup Lars Nannestad Jorgensen Magnus Sven ?gren 《World journal of gastroenterology : WJG》2014,20(35):12637-12648
AIM: To identify pharmaceuticals for the prophylaxis of anastomotic leakage (AL), we systematically reviewed studies on anastomosis repair after colorectal surgery.METHODS: We searched PubMed and EMBASE for articles published between January 1975 and December 2012. We included studies in English with the primary purpose of promoting healing of anastomoses made in the colon or rectum under uncomplicated conditions. We excluded studies on adverse events from interventions, nutritional interventions or in situ physical supporting biomaterials. The primary outcome was biomechanical strength or AL. We performed meta-analyses on therapeutic agents investigated by three or more independent research groups using the same outcome. The DerSimonian-Laird method for random effects was applied with P < 0.05.RESULTS: Of the 56 different therapeutic agents assessed, 7 met our inclusion criteria for the meta-analysis. The prostacyclin analog iloprost increased the weighted mean of the early bursting pressure of colonic anastomoses in male rats by 60 mmHg (95%CI: 30-89) vs the controls, and the immunosuppressant tacrolimus increased this value by 29 mmHg (95%CI: 4-53) vs the controls. Erythropoietin showed an enhancement of bursting pressure by 45 mmHg (95%CI: 14-76). The anabolic compound growth hormone augmented the anastomotic strength by 21 mmHg (95%CI: 7-35), possibly via the up-regulation of insulin-like growth factor-1, as this growth factor increased the bursting pressure by 61 mmHg (95%CI: 43-79) via increased collagen deposition. Hyperbaric oxygen therapy increased the bursting pressure by 24 mmHg (95%CI: 13-34). Broad-spectrum matrix metalloproteinase inhibitors increased the bursting pressure by 48 mmHg (95%CI: 31-66) on postoperative days 3-4. In the only human study, the AL incidence was not significantly reduced in the 103 colorectal patients treated with aprotinin (11.7%) compared with the 113 placebo-treated patients (9.7%).CONCLUSION: This systematic review identified only one randomized clinical trial and seven therapeutic agents from pre-clinical models that could be explored further for the prophylaxis of AL after colorectal surgery. 相似文献
8.
9.
Patnaik MM Hanson CA Sulai NH Hodnefield JM Knudson RA Ketterling RP Lasho TL Tefferi A 《Blood》2012,119(24):5674-5677
The presence of ≥ 15% bone marrow (BM) ring sideroblasts (RS) and < 5% blasts is required for a diagnosis of refractory anemia with ring sideroblasts. We examined the phenotypic and prognostic relevance of this "15%" RS threshold in 200 patients with myelodysplastic syndromes (MDS) without excess blasts and with ≥ 1% RS. The impact of RS% was assessed both as a continuous and categorical variable: < 5% (n = 56), 5%-14% (n = 32), 15%-50% (n = 79), and > 50% (n = 33). RS% correlated (P < .05) directly with age, platelet count, transfusion dependency, BM cellularity, and mutant SF3B1 and inversely with hemoglobin level, multilineage dysplasia, and high-risk karyotype; but did not correlate with IDH mutations. At a median follow-up of 33 months, 156 (73%) deaths and 24 (12%) leukemic transformations were documented. Neither univariate nor multivariable analysis showed significant effect for RS% on overall or leukemia-free survival, suggesting the limited prognostic value of quantifying BM RS in MDS. 相似文献
10.